



Paradoxical Hypersusceptibility of Drug-resistant Mycobacterium tuberculosis to β -lactam Antibiotics

Citation

Cohen, K. A., T. El-Hay, K. L. Wyres, O. Weissbrod, V. Munsamy, C. Yanover, R. Aharonov, et al. 2016. "Paradoxical Hypersusceptibility of Drug-resistant Mycobacterium tuberculosis to β -lactam Antibiotics." *EBioMedicine* 9 (1): 170-179. doi:10.1016/j.ebiom.2016.05.041. <http://dx.doi.org/10.1016/j.ebiom.2016.05.041>.

Published Version

[doi:10.1016/j.ebiom.2016.05.041](https://doi.org/10.1016/j.ebiom.2016.05.041)

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002528>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



Research Paper

Paradoxical Hypersusceptibility of Drug-resistant *Mycobacterium tuberculosis* to β -lactam Antibiotics

Keira A. Cohen^{a,b,*}, Tal El-Hay^{c,1}, Kelly L. Wyres^{d,e,f,1}, Omer Weissbrod^c, Vanisha Munsamy^b, Chen Yanover^c, Ranit Aharonov^c, Oded Shaham^c, Thomas C. Conway^d, Yaara Goldschmidt^c, William R. Bishai^g, Alexander S. Pym^{b,**}

^a Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

^b KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban, South Africa

^c IBM Research-Haifa, Haifa, Israel

^d IBM Research - Australia, Carlton, Victoria, Australia

^e Centre for Systems Genomics, University of Melbourne, Parkville, Victoria, Australia

^f Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia

^g Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD, USA

ARTICLE INFO

Article history:

Received 10 March 2016

Received in revised form 18 May 2016

Accepted 31 May 2016

Available online 1 June 2016

Keywords:

tuberculosis

Multi-drug resistant (MDR)

Extensively drug resistant (XDR)

Beta-lactam antibiotics

Antimicrobial chemotherapy

pk12

Recombination

ABSTRACT

Mycobacterium tuberculosis (*M. tuberculosis*) is considered innately resistant to β -lactam antibiotics. However, there is evidence that susceptibility to β -lactam antibiotics in combination with β -lactamase inhibitors is variable among clinical isolates, and these may present therapeutic options for drug-resistant cases. Here we report our investigation of susceptibility to β -lactam/ β -lactamase inhibitor combinations among clinical isolates of *M. tuberculosis*, and the use of comparative genomics to understand the observed heterogeneity in susceptibility. Eighty-nine South African clinical isolates of varying first and second-line drug susceptibility patterns and two reference strains of *M. tuberculosis* underwent minimum inhibitory concentration (MIC) determination to two β -lactams: amoxicillin and meropenem, both alone and in combination with clavulanate, a β -lactamase inhibitor. 41/91 (45%) of tested isolates were found to be hypersusceptible to amoxicillin/clavulanate relative to reference strains, including 14/24 (58%) of multiple drug-resistant (MDR) and 22/38 (58%) of extensively drug-resistant (XDR) isolates. Genome-wide polymorphisms identified using whole-genome sequencing were used in a phylogenetically-aware linear mixed model to identify polymorphisms associated with amoxicillin/clavulanate susceptibility. Susceptibility to amoxicillin/clavulanate was over-represented among isolates within a specific clade (LAM4), in particular among XDR strains. Twelve sets of polymorphisms were identified as putative markers of amoxicillin/clavulanate susceptibility, five of which were confined solely to LAM4. Within the LAM4 clade, 'paradoxical hypersusceptibility' to amoxicillin/clavulanate has evolved in parallel to first and second-line drug resistance. Given the high prevalence of LAM4 among XDR TB in South Africa, our data support an expanded role for β -lactam/ β -lactamase inhibitor combinations for treatment of drug-resistant *M. tuberculosis*.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Abbreviations: XDR, extensively drug resistant; MIC, minimum inhibitory concentration; MDR, multidrug resistant; SNP, single nucleotide polymorphism; SNV, single nucleotide variant; WGS, whole-genome sequencing.

* Correspondence to: K.A. Cohen, Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

** Corresponding author.

E-mail addresses: kacohen@partners.org (K.A. Cohen), alex.pym@k-rith.org

(A.S. Pym).

¹ These authors contributed equally to this work.

1. Introduction

Approximately one third of the global population is infected with *Mycobacterium tuberculosis* (*M. tuberculosis*), the etiologic agent responsible for tuberculosis (TB). While many individuals who harbour *M. tuberculosis* never develop active disease, TB is often lethal and is estimated to have been responsible for 1.5 million deaths in the year 2013 (WHO, 2014). Multidrug-resistant (MDR) TB, which is defined as *in vitro* resistance to both rifampin and isoniazid, is a public health problem of increasing importance, with an estimated 480,000 incident cases in 2013 (WHO, 2014). Treatment of drug-resistant TB is more complex, lengthy, costly, toxic, and ultimately less successful at eradicating *M.*

tuberculosis infection. With few novel antitubercular antibiotics in development, the emergence of extensively drug-resistant (XDR) *M. tuberculosis* strains (defined as MDR with additional resistance to both quinolones and second-line injectable agents) and the lack of effective treatment regimens have highlighted the potential to repurpose existing antibiotics in innovative ways (Wong et al., 2013).

M. tuberculosis has been considered innately resistant to β -lactam antibiotics, due to β -lactamase activity and the presence of non-classical transpeptidases in their cell wall (Hugonnet et al., 2009; Gupta et al., 2010). *M. tuberculosis* possesses a highly active β -lactamase, BlaC, that rapidly hydrolyzes many β -lactam drugs, rendering them ineffective (Hugonnet et al., 2009). Additionally, the existence of non-classical transpeptidases that crosslink the peptidoglycan cell wall of *M. tuberculosis* are thought to contribute to innate resistance to β -lactams (Gupta et al., 2010; Dub  e et al., 2012).

Despite these barriers, there may be opportunities for clinical treatment of drug-resistant *M. tuberculosis* with β -lactam antibiotics (Payen et al., 2012; Keener, 2014). The addition of clavulanate, an oral β -lactamase inhibitor, irreversibly inhibits BlaC, and can enhance β -lactam activity against *M. tuberculosis* *in vitro* (Wang et al., 2006; Hugonnet and Blanchard, 2007). Furthermore, the carbapenem class of β -lactams is relatively resistant to hydrolysis by β -lactamases, and addition of clavulanate has been shown to further decrease the minimum inhibitory concentration (MIC) (Hugonnet et al., 2009). Meropenem/clavulanate has been shown to have high *in vitro* activity against XDR strains, but its high cost and intravenous dosing present challenges to its widespread use (Hugonnet et al., 2009; Gonzalo and Drobniewski, 2013). The laboratory strain of *M. tuberculosis*, H37Rv, and multiple drug-susceptible clinical isolates have been shown to be resistant to β -lactams as well as β -lactams plus β -lactamase inhibitors *in vitro*, but it is not yet clear to what extent the wider *M. tuberculosis* population may be susceptible to these antibiotics. If drug-resistant strains are generally more susceptible to this antibiotic class, then one might envision an expanded role for β -lactams in the treatment of drug-resistant TB, for which currently there are limited treatment options.

Here we describe an investigation of 89 South African clinical isolates and two reference strains of *M. tuberculosis* of varying drug susceptibility patterns. We determined the range of MICs to clinically available β -lactam antibiotics and used whole-genome sequencing (WGS) to understand the genetic basis of variability with respect to amoxicillin/clavulanate susceptibility. Our results provide insight into the clinical role of β -lactams in the treatment of drug-resistant TB and potential molecular markers of amoxicillin/clavulanate susceptibility.

2. Methods

2.1. Clinical Isolates of *M. tuberculosis*

We selected a subset of 86 clinical isolates of *M. tuberculosis* from our larger sequenced strain set (Cohen et al., 2015) for inclusion in this study. Briefly, sputum specimens were collected in KwaZulu-Natal, South Africa from 2008 to 2012 as part of a provincial drug-resistance surveillance study (Bantubani et al., 2014) and a prospective collection effort of patients newly initiating XDR regimens (O'Donnell et al., 2014). Biomedical Research Ethics Council (BREC) approval from the University of KwaZulu-Natal was granted for whole genome sequencing of clinical strains. On all study isolates, drug susceptibility testing by critical concentration was performed prospectively for first and second-line TB drugs. The clinical isolate set represented diverse first and second-line drug susceptibility patterns, with 18 susceptible, three mono-drug resistant, five poly-drug resistant, 23 MDR and 37 XDR isolates.

2.2. Additional *M. tuberculosis* Strain

In addition to 86 clinical isolates recently isolated in South Africa, we also selected five additional strains for inclusion in this study, for a total of 91 unique isolates. These included reference strains H37Rv and CDC1551, which are both known to be fully susceptible to first and second-line TB drugs. Additionally, three clinical isolates that had previously been collected in KwaZulu-Natal (Koenig, 2007; Iøerger et al., 2009) were resequenced and included in this study. These were KZN4207, KZN1435 and KZN605, which have first/second-line drug susceptibility patterns of: susceptible, MDR and XDR, respectively.

2.3. β -lactam MIC Determination

The World Health Organization (WHO) does not recommend a standard methodology for β -lactam susceptibility or resistance testing in *M. tuberculosis*, thus we utilized the Microplate Alamar Blue Assay (MABA) (Collins and Franzblau, 1997) to determine the MIC of each strain to β -lactams alone, or β -lactams in combination with clavulanate, a β -lactamase inhibitor, as previously described (Lun et al., 2013). The β -lactams and concentrations utilized were amoxicillin (0.5 μ g/mL to 32 μ g/mL) and meropenem (0.25 μ g/mL to 16 μ g/mL). Briefly, 10^4 colony forming units (CFU) of a mid to late-log culture of each strain was plated onto a 96-well microplate in the presence of serial drug-dilutions with or without 2.5 μ g/mL of clavulanate. Following seven days in culture, the lowest concentration of drug leading to at least a 90% reduction of bacterial growth signal by MABA was recorded as the MIC. Each assay was performed between one to 6 times on each isolate.

2.4. β -lactam Susceptibility Definitions

Based on favourable pharmacokinetics that would be necessary for clinical treatment (White et al., 2004), susceptibility to amoxicillin was defined as an MIC ≤ 4.0 μ g/mL, and resistance as an MIC > 4.0 μ g/mL; susceptibility to amoxicillin/clavulanate was defined as an MIC ≤ 4.0 μ g/mL/2.5 μ g/mL, and resistance as an MIC > 4.0 μ g/mL/2.5 μ g/mL. Susceptibility to meropenem was defined as an MIC ≤ 12.0 μ g/mL, and resistance as an MIC > 12.0 μ g/mL; susceptibility to meropenem/clavulanate was defined as an MIC ≤ 12.0 μ g/mL/2.5 μ g/mL, and resistance as an MIC > 12.0 μ g/mL. We note that our association analysis used the amoxicillin/clavulanate MIC values directly, without dichotomization of resistant vs. susceptible.

2.5. β -lactamase Activity Testing

A subset of 10 *M. tuberculosis* isolates with varying average MICs to amoxicillin/clavulanate (range 0.5 μ g/mL to > 32 μ g/mL of amoxicillin in combination with 2.5 μ g/mL clavulanate) underwent qualitative testing of their β -lactamase activity by nitrocefin hydrolysis. Nitrocefin (Calbiochem), a chromogenic β -lactamase substrate, was reconstituted in dimethyl sulfoxide (DMSO) to achieve 1 mg/mL. 60 μ L of nitrocefin was diluted into 3 mL of phosphate buffered saline (PBS) nitrocefin to create a working solution. Mid to late log cultures of *M. tuberculosis* were diluted in PBS, and 10^5 colony forming units of each strain were plated into a 96-well plate. 100 μ L of the nitrocefin working solution was added. Cultures were monitored for a color change from yellow to red that occurs with nitrocefin hydrolysis.

2.6. Whole-genome Sequencing

Whole-genome sequencing had been performed on all included strains as previously described and published in Cohen et al. (Cohen et al., 2015). Briefly, mycobacterial strains were single colony selected, and genomic DNA was extracted using published methods (Larsen et al., 2007). Library preparation and whole-genome sequencing were performed on the Illumina HiSeq 2000 at the Broad Institute in Boston, MA,

as previously described (Walker et al., 2014). Both short (180 bp) and large (3–5 Kbp) insert paired-end libraries were created from each sample and sequenced using a read length of 101 bp. All sequencing data were retrieved from the Sequence Read Archive NCBI umbrella BioProject identifier PRJNA183624.

2.7. *In silico* Spoligotyping

In vitro spoligotypes are derived by a hybridization assay which determines whether or not each of 43 probe sequences (each 25 bp in length) hybridizes against a sample of DNA (Kamerbeek et al., 1997). Here spoligotypes were determined *in silico* from Illumina sequence reads by extraction of 25 bp sequences and their reverse complements from all possible positions, and subsequent search across this set for a match for each probe sequence. In the *in vitro* assay, probes may hybridize even if the sequences do not match exactly, and thus we allowed up to two nucleotide mismatches per probe. Hybridization patterns were assigned to known *M. tuberculosis* clades/lineages by comparison of exact pattern matches in the international SITVIT database (Demay et al., 2012) and interrogation of the TB Insight: TB-Lineage database (Shabbeer et al., 2012). Lineage designations were converted to the standardised nomenclature as presented in Gagneux et al. (Gagneux and Small, 2007).

2.8. Single nucleotide variant calling

Illumina reads for each of 91 strains were trimmed using *seqtk* (<https://github.com/lh3/seqtk> version 1.0-r31) with a Phred quality threshold of 0.01. Trimmed reads were mapped to the H37Rv reference genome (accession NC_000962.3) using BWA (Li and Durbin, 2009). Subsequent processing by SAMTools (Li et al., 2009) removed duplications, merged reads from different sequencing runs of the same isolate and removed unpaired reads. SNPs and small indels (SNVs) were called using SNVer (Wei et al., 2011) in a monoploid mode with default parameters, with the exception that the minimum base quality threshold was increased to q20. We also enforced a minimum frequency of five reads, in each of the forward and reverse orientations, supporting each SNV call. Variants for which the maximum a-posteriori genotype estimation as computed by SNVer did not support any allele, for which depth was less than 10, strand bias was smaller than 0.05, or $p > 10^{-10}$ were excluded from subsequent analyses.

2.9. Phylogenetic Reconstruction

Bayesian inference of phylogeny as implemented in MrBayes (Ronquist et al., 2012) was performed based on substitution patterns of single nucleotides at conserved genomic sites (*i.e.* for which high confidence SNP calls were obtained across all isolates). Genomic regions that are known to be prone to erroneous mapping of reads, namely repeat regions, mobile elements, phage proteins, PE and PPE proteins, were excluded (Casali et al., 2012). *Mycobacterium canettii* CIPT 140010059 (accession: NC_015848) was used as an outgroup for phylogenetic reconstruction. A generalized time-reversible (GTR) evolutionary model with gamma distributed rate variation across sites was applied (1,000,000 Markov chain Monte Carlo runs sampled every 1000 generations after a relative burn-in of 0.25, yielding a total of 750 replicates). As association tests require a phylogeny that estimates relatedness among isolates in terms of evolutionary time (Kang et al., 2008), a molecular clock constraint was imposed on branch lengths, enforcing all the leaves to be equidistant from the root. For visualization purposes, a tree with branch lengths that reflected the number of substitutions was also inferred (Figs. 2 and 3).

2.10. Gene-content Analysis

De novo sequence assemblies were annotated by Prokka (Seemann, 2014). Nucleotide sequences for all annotated coding sequence (CDS) regions were added to those annotated within 18 *M. tuberculosis* reference genomes retrieved from Genbank (accessions; NC_000962.3, NC_002755.2, NC_009565.1, NC_012943.1, NC_016768.1, NC_016934.1, NC_017522.1, NC_017523.1, NC_017524.1, NC_018078.1, NC_020089.1, NC_020559.1, NC_021054.1, NC_021192.1, NC_021193.1, NC_021194.1, NC_021740.1, NC_022350.1). A BLASTn all-against-all analysis was used to cluster CDS (percentage identity $\geq 90\%$ and coverage $\geq 85\%$). Single representatives of each cluster were collated to form a non-redundant CDS list (preferentially selecting H37Rv reference CDS when present within a cluster). Non-H37Rv cluster representatives were screened against the H37Rv reference genome and removed if there was a BLASTn match with $\geq 90\%$ identity and $\geq 85\%$ coverage. (The H37Rv genome annotation has been well curated and thus we assume any sequence showing homology to regions of this genome, but which has not been annotated as a CDS in this genome, represents an erroneous annotation.) The presence of sequence regions representing each of the filtered, non-redundant CDS clusters ($n = 3957$) was estimated by BLASTn search against the *de novo* genome assemblies (percentage identity $\geq 90\%$, coverage $\geq 85\%$). Genes were considered putatively absent in cases where there was no BLAST match above the identity and coverage thresholds.

2.11. Association Tests

Genomic variants were tested for association with log MIC to amoxicillin/clavulanate. The association analysis used the amoxicillin/clavulanate MIC values directly rather than the dichotomous phenotype of resistant vs. susceptible. All SNVs for which base calls were available in all isolates were included in the analysis (including those in repeat regions, mobile elements, phage and PE/PPE genes). All genes represented by CDS in the filtered non-redundant list (see above) were also included in the analysis.

The initial sample consisted of 8580 SNVs and 8936 gene-content patterns. After excluding low frequency variants in which less than three isolates varied from all other isolates, 2555 SNVs and 228 gene-content patterns remained in the analysis. The close relatedness between many of the isolates in our sample leads to strong statistical dependencies between many pairs of variants, whose alleles have the same patterns across the sample. Such variants by definition comprise the same statistical hypothesis and result in the same p -value. We thus performed analysis of unique variant patterns, rather than of individual variants, and attached the p -value of each unique pattern to all SNVs having this pattern. Overall, 239 SNV patterns and 122 gene-content patterns (with an overlap of four patterns) were tested for association with drug resistance. FDR analysis was performed by considering the total number of tested hypotheses under both analyses.

A major challenge of genome-wide association testing is the presence of a population structure (Chen and Shapiro, 2015) in which sampled isolates are not identically and independently distributed. This can lead to spurious results due to confounding, *e.g.* in this case alleles that are common to a group of closely related susceptible isolates may falsely appear to be associated with β -lactam susceptibility. To account for population structure in the setting of a quantitative phenotype (*e.g.* log-MIC), we applied a *phylogenetically aware* LMM (Kang et al., 2008). Given that *M. tuberculosis* is known to have a low rate of horizontal gene transfer (Liu et al., 2006), the effect of the population structure is assumed to be well-approximated by phylogeny. p -values were computed *via* simulation testing with one million simulations. See Supplemental Methods for more details.

3. Results

3.1. Clinical Isolates of *M. tuberculosis* Exhibit a Broad Range of MICs to β -lactams

We screened a set of 91 *M. tuberculosis* strains of varying drug susceptibility patterns by determining the MIC to β -lactam/ β -lactamase inhibitor combinations (Table S1). Included clinical isolates of *M. tuberculosis* had been collected from 2008 to 2012 in KwaZulu-Natal, South Africa (Cohen et al., 2015). Phenotypic assessment of a strain's susceptibility to amoxicillin, amoxicillin/clavulanate, meropenem and meropenem/clavulanate was performed by the drug Microplate Alamar Blue Assay (MABA), as previously described (Collins and Franzblau, 1997; Lun et al., 2014).

Phenotypic testing of strains revealed universally high MICs to amoxicillin by itself (Fig. 1A), which confirms innate mycobacterial resistance to this antibiotic alone among these strains. However, with the addition of clavulanate the mean MIC to amoxicillin lowered from 55.4 to 15.2 (Table S2), as numerous isolates were observed to have very low MICs to amoxicillin/clavulanate (Fig. 1B). With drug combination amoxicillin/clavulanate, 41/91 (45%) isolates had an MIC ≤ 4 $\mu\text{g}/\text{mL}$ /2.5 $\mu\text{g}/\text{mL}$ and as such were classified as susceptible to this regimen (Table 1; Table S1). Given the wide range of MICs observed for amoxicillin/clavulanate, a significant number of *M. tuberculosis* isolates may be amenable to treatment with this orally active β -lactam/ β -lactamase inhibitor combination.

MIC determination was also performed for meropenem and meropenem/clavulanate. With meropenem alone, there was also a range of MICs observed among the tested isolates (Fig. 1C). With addition of clavulanate to meropenem (Fig. 1D), the mean observed MIC

was lowered from 22.0 $\mu\text{g}/\text{mL}$ for meropenem alone to 5.4 $\mu\text{g}/\text{mL}$ /2.5 $\mu\text{g}/\text{mL}$ for meropenem/clavulanate (Table S2). The resulting MIC's to meropenem and meropenem/clavulanate were consistent with those derived in a previous study (Hugonnet and Blanchard, 2007).

3.2. Paradoxical Hypersusceptibility to β -lactams among MDR and XDR Isolates

Interestingly, strains that had previously been classified as MDR or XDR on first and second-line TB drug susceptibility testing were more frequently associated with amoxicillin/clavulanate susceptibility than isolates that were fully susceptible to first and second-line drugs (Table 1). 14/24 (58%) MDR and 22/38 (58%) XDR isolates were classified as susceptible to amoxicillin/clavulanate, whereas only 3/21 (14%) first-line drug susceptible isolates were classified as susceptible to the same drug combination. Given that the overwhelming majority (18/21, 86%) of first-line susceptible strains including the reference laboratory strains H37Rv and CDC1551 were resistant to amoxicillin/clavulanate, it appeared paradoxical that MDR and XDR isolates would be susceptible to this drug combination. This was therefore termed "hypersusceptibility," to indicate gain of susceptibility.

3.3. In vitro Assessment of β -lactamase Activity

To determine whether observed differences in the MIC to amoxicillin/clavulanate were due to differential β -lactamase activity, a phenotypic assessment was performed by the nitrocefin hydrolysis assay (see Section 2). A subset of 10 isolates with varying drug susceptibility patterns and a range of MICs to amoxicillin/clavulanate were selected for assessment (Table S3). All assayed strains, irrespective of drug




Fig. 1A–1D. Clinical isolates of *M. tuberculosis* exhibit a range of susceptibility to β -lactam/ β -lactamase inhibitors. 91 isolates of *M. tuberculosis* underwent MIC determination to A) amoxicillin, B) amoxicillin/clavulanate, C) meropenem, and D) meropenem/clavulanate. MICs are reported by β -lactam concentration, and clavulanate concentration was held constant at 2.5 $\mu\text{g}/\text{mL}$.

Table 1
A disproportionate number of MDR and XDR strains were susceptible to amoxicillin/clavulanate. Susceptibility to amoxicillin or amoxicillin/clavulanate was defined as MIC ≤ 4 $\mu\text{g}/\text{mL}$ of the amoxicillin component. Susceptibility to meropenem or meropenem/clavulanate was defined as MIC ≤ 12 $\mu\text{g}/\text{mL}$ of the meropenem component. Clavulanate was 2.5 $\mu\text{g}/\text{mL}$.

First and second-line DST category	Amoxicillin susceptibility	Amoxicillin/Clavulanate susceptibility	Meropenem susceptibility	Meropenem/Clavulanate susceptibility
Susceptible	0/21 (0%)	3/21 (14%)	3/16 (19%)	14/16 (87.5%)
Mono-drug resistant	0/3 (0%)	0/3 (0%)	0/3 (0%)	3/3 (100%)
Poly-drug resistant	0/5 (0%)	2/5 (40%)	1/5 (20%)	5/5 (100%)
MDR	0/24 (0%)	14/24 (58%)	5/18 (28%)	19/21 (90%)
XDR	1/38 (3%)	22/38 (58%)	11/36 (31%)	36/37 (97%)
Total	1/91 (1%)	41/91 (45%)	20/78 (26%)	77/82 (94%)

susceptibility pattern or MIC to amoxicillin/clavulanate were able to hydrolyze nitrocefin, indicative of positive β -lactamase activity. This suggested that lack of β -lactamase activity did not account for low MICs to amoxicillin/clavulanate. These results are consistent with our observation that clavulanate addition is necessary to achieve a low MIC to amoxicillin.

3.4. Population Structure Reveals a Monophyletic Clade of LAM4 MDR and XDR Strains

We conducted a comparative genomic analysis to understand the evolution of hypersusceptibility to amoxicillin/clavulanate in our panel of clinical isolates. All 91 β -lactam phenotyped strains had




Fig. 2. Amoxicillin/clavulanate hypersusceptible isolates were largely clustered within a monophyletic XDR group within the LAM4 clade. A Bayesian phylogeny of 91 *M. tuberculosis* isolates, rooted with the *M. canettii* outgroup, is shown. Bootstrap support values $>80\%$ are marked by an asterisk. Globally recognised *M. tuberculosis* lineages are indicated. Amoxicillin/clavulanate MICs are represented in a horizontal bar graph to the right of the tree. MICs are reported by amoxicillin concentration, and clavulanate concentration was held constant at 2.5 $\mu\text{g}/\text{mL}$. As indicated in the figure key, the MIC bar graph is color-coded according to the first and second-line drug susceptibility patterns of the corresponding strain. The shaded box indicates LAM4 strains; a monophyletic cluster of spoligotype LAM4 strains with MDR and XDR level resistance is observed within lineage 4. While a significant number of isolates with hypersusceptibility to amoxicillin/clavulanate were concentrated within the LAM4 XDR clade, there are other notable examples of hypersusceptible strains that pertain to other global lineages and spoligotypes.

Table 2Frequency and distribution of DST patterns and amoxicillin/clavulanate susceptibility determination across *M. tuberculosis* global lineages and SITVIT clades.

<i>M. tuberculosis</i> lineage	Spoligotype designation	Total number of strains per spoligotype	First/second-line DST patterns				Amoxicillin/clavulanate susceptibilities	
			Susceptible	Mono/Poly	MDR	XDR	Susceptible	Resistant
1	EAI1-SOM	2	–	1 (50%)	1 (50%)	–	2 (100%)	–
2	Beijing	20	6 (30%)	5 (25%)	5 (25%)	4 (20%)	2 (10%)	18 (90%)
3	CAS1-Kili	1	–	1 (100%)	–	–	–	1 (100%)
4	H1	1	1 (100%)	–	–	–	1 (100%)	–
	H37Rv	2	2 (100%)	–	–	–	–	2 (100%)
	LAM3	4	3 (75%)	–	–	1 (25%)	–	4 (100%)
	LAM4	47	4 (9%)	1 (2%)	13 (28%)	29 (62%)	32 (68%)	15 (32%)
	S	4	–	–	4 (100%)	–	1 (25%)	3 (75%)
	T1	3	2 (67%)	–	1 (33%)	–	1 (33%)	2 (67%)
	T3	1	–	–	–	1 (100%)	–	1 (100%)
	X3	5	2 (40%)	–	–	3 (60%)	1 (20%)	4 (80%)
	UND	1	1 (100%)	–	–	–	1 (100%)	–
	Total		91	21 (23%)	8 (9%)	24 (26%)	37 (41%)	41 (45%)

Lineages and SITVIT clades inferred from *in silico* spoligotype data (see Section 2). UND = undesignated spoligotype. First/second-line drug susceptibility (DST) results are abbreviated as follows: susceptible, mono or poly-drug resistant (Mono/Poly), multi-drug resistant (MDR) and extensively drug resistant (XDR). For amoxicillin/clavulanate susceptibility, strains were designated susceptible and resistant based on an MIC ≤ 4 $\mu\text{g}/\text{mL}$ of the amoxicillin component.

whole-genome sequences available for analysis (Cohen et al., 2015). A Bayesian phylogeny (Fig. 2) was inferred from 7005 polymorphic sites identified through read-mapping and variant calling (Methods). In parallel, we performed an *in silico* spoligotype prediction (Methods) to contextualize the resulting population structure with respect to previously defined global *M. tuberculosis* lineages (Gagneux and Small, 2007; Hershberg et al., 2008) and SITVIT clades (Demay et al., 2012; Shabbeer et al., 2012). Strains represented 15 distinct shared types distributed across 11 SITVIT clades, each nesting within one of four global *M. tuberculosis* lineages (Table 2; Table S1).

There was an asymmetric distribution of MDR and XDR observed across the phylogeny (Fig. 2), as a disproportionate number of MDR and XDR isolates pertained to Lineage 4. More specifically, *in silico* spoligotyping revealed that these strains pertained to the LAM4 SITVIT clade and accounted for a great majority of MDR and XDR among the study isolates, with 68% and 85%, respectively. Of note, the LAM4 XDR strains clustered phylogenetically with reference strain KZN605 (Koenig, 2007; loerger et al., 2009), which was isolated in Tugela Ferry, KZN, South Africa in 2005 during the famed nosocomial XDR outbreak (Gandhi et al., 2006). A prior sequencing study by Cohen et al. (2015) has demonstrated that these same isolates are members of the clonal Tugela Ferry XDR epidemic in the region.

3.5. β -lactam Hypersusceptibility is Concentrated Within the Monophyletic Cluster of LAM4

While at least one strain susceptible to amoxicillin/clavulanate was observed in each of Lineages 1, 2 and 4, the vast majority (37/41 [90.2%]) of susceptible strains fell within Lineage 4 (Fig. 2 and Table 2). In fact, 32/41 (78%) of amoxicillin/clavulanate susceptible isolates pertained to the LAM4 clade, suggesting a monophyletic origin of hypersusceptibility.

In general, it can be difficult to disambiguate which genetic variants are responsible for a specific trait within a monophyletic clade as all genetic elements shared among the clade members will appear to be associated with that trait. However, the substantial phenotypic variability with respect to amoxicillin/clavulanate MIC despite limited genotypic variability in the LAM4 clade was suggestive that it may still be possible to identify key genomic variants responsible for or markers of the phenotype.

3.6. Comparative Genomic Analysis: Application of a Phylogenetically-aware Linear Mixed Model to Identify Candidate Variants

We next sought to test genomic markers of amoxicillin/clavulanate susceptibility using a phylogenetically-aware linear mixed model (LMM) (Kang et al., 2008) to identify candidate genomic variants. As our sample was dominated by a monophyletic phenotype of hypersusceptibility (Fig. 2), a phylogenetically-aware LMM was selected as this approach takes the phylogenetic structure into account and allows ranking of genomic phenotype-differentiating variants while remaining resilient to spurious variants (Chen and Shapiro, 2015). Single nucleotide polymorphisms (SNPs) and single nucleotide indels were considered together as single nucleotide variants (SNVs), and the goal of the analysis was focused on identifying genetic elements that differentiate closely related isolates that exhibit large phenotypic differences.

Rather than testing each independent SNV, variants were tested in groups defined by their pattern of representation across the set of genomes (*i.e.* variants shared by the same subset of genomes were grouped together). After excluding variants present in two or fewer genomes, we identified 239 distinct SNV groups. Due to the large number of tested hypotheses relative to the sample size, we controlled for the false discovery rate (FDR) rather than the family-wise error rate, using the Benjamini–Hochberg procedure (Benjamini and Hochberg, 1995). All p -values smaller than 1.68×10^{-3} were determined to be significant at a 5% FDR, yielding 12 significant SNV groups. Of note, separately from the association analysis of SNVs, the LMM was also applied to a gene-content analysis (See Supplemental Results).

3.7. Identification of Twelve Significant Groups of Variants by LMM Analysis

The LMM analysis identified 12 significant groups of variants as highly associated with amoxicillin/clavulanate susceptibility, one of which included only a single synonymous variant (Table 3, Tables S4 and S5). These twelve groups with significant p -values comprised a total of 38 individual SNVs which included: 17 non-synonymous mutations within predicted coding sequences, 16 synonymous mutations (Table S5); four intergenic polymorphisms, and a single nucleotide deletion within a predicted pseudogene (PE_PGRS36). Coding sequences included those associated with the following functions as defined in the TubercuList database (Lew et al., 2011) or as otherwise cited: first and second-line drug resistance (*rpoB*, *gyrA*, *ubiA* (Safi et al., 2013)), virulence, transmembrane proteins (*ctpB*, *drxA*, Rv3921c) and cell wall

Table 3
Single nucleotide variants (non-synonymous and intergenic) identified as putative genomic markers of amoxicillin/clavulanate susceptibility.

Genomic loci	Rv number	Gene name	Effect*	Amino acid effect	# Isolates	p-Value	LAM4 sub-clade
664929	Rv0571c-Rv0572c	–	C → A	Intergenic	28	1.28E–04	D
761161	Rv0667	<i>rpoB</i>	cTg → cCg	L452P	36	2.40E–04	B
1272321	Rv1144-Rv1145	– <i>mmpL13a</i>	C → A	Intergenic	36	2.40E–04	B
2,300,674	Rv2048c	<i>pkS12</i>	Aac → Gac	N2105D	36	2.40E–04	B
2300676	Rv2048c	<i>pkS12</i>	tAc → tTc	Y2104F	36	2.40E–04	B
3889150	Rv3471c	–	gaC → gaA	D64E	36	2.40E–04	B
761110	Rv0667	<i>rpoB</i>	gAc → gCc	D435G	30	2.88E–04	C
763123	Rv0667	<i>rpoB</i>	aTc → aCc	I1106T	30	2.88E–04	C
2246032	Rv2000	–	cTg → cCg	L275P	30	2.88E–04	C
4056430	Rv3616c-Rv3617	<i>espA-ephA</i>	T → C	Intergenic	30	2.88E–04	C
1212626	Rv1087	PE_PGRS21	gAc → gCc	D356A	36	3.04E–04	–
7570	Rv0006	<i>gyrA</i>	cGc → gTg	A90 V	32	4.96E–04	–
4269271	Rv3806c	<i>ubiA</i>	gTg → gCg	V188 A	31	6.08E–04	–
1532777	Rv1361c	PPE19	cAg → cCg	Q286R	45	1.10E–03	–
122107	Rv0103c	<i>ctpB</i>	Ggt → Agt	G23S	42	1.17E–03	A
3272997	Rv2936	<i>drpA</i>	Agg → Ggg	R262G	42	1.17E–03	A
283614	Rv0236c	<i>aftD</i>	Agc → Ggc	S1080G	8	1.25E–03	–
340372	Rv0280	PPE3	Tcg → Ccg	S337P	8	1.25E–03	–
2357269	Rv2098c	PE_PGRS36 (pseudogene)	G →	Deletion	8	1.25E–03	–
3462135	Rv3093c	–	tgC → tgG	C210W	8	1.25E–03	–
3942640	Rv3512	PE_PGRS56	aTt → aCt	I306T	8	1.25E–03	–
2074509	Rv1829-Rv1830	–	C → G	Intergenic	45	1.40E–03	–

Genomic loci as defined in the H37Rv reference genome. For single nucleotide polymorphisms 'Effect' indicates the base differences (base in reference → alternative base), polymorphisms within coding sequence regions are shown as capital letters in the context of the codons to which they belong (other positions shown in lower case). # Isolates indicates the number of *M. tuberculosis* strains that contained the corresponding polymorphism. LAM4 sub-clade indicates the sub-clade for which the SNP in question is both unique to and conserved across the sub-clade. All SNVs having the same p-value represent the same evolutionary pattern. Of note, our analyses did not identify any associations between amoxicillin/clavulanate susceptibility and variation in genes previously implicated for this phenotype e.g. mycobacterial L,D-transpeptidases, carboxypeptidases, penicillin-binding proteins and the BlaC beta-lactamase among others (Dubée et al., 2012; Datta et al., 2006; Kumar et al., 2012; Flores et al., 2005; Bhakta and Basu, 2002; Danilchanka et al., 2008; Dinesh et al., 2013; Fukuda et al., 2013; McDonough et al., 2005) (Table S6).

synthesis (*aftD*, PE-PGRS genes (Brennan and Delogu, 2002) *pkS12* (Matsunaga and Sugita, 2012) and *ubiA*). As mapping and variant calling within the PE/PPE genes is notoriously difficult due to extent of sequence repeats within these genes, our findings regarding SNVs in these genes should be considered cautiously. Intergenic SNVs included one upstream of *mmpL13a*, a transmembrane transport protein, and one within two nucleotides of the *espA* transcriptional start site (Pang et al., 2013).

3.8. Clustering of Variants Within *pkS12* Likely Due to Recombination

Interestingly, eight of the identified variants were located within a 34 bp region of the 5' *pkS12*, which included two non-synonymous and six synonymous mutations. *pkS12* encodes a polyketide synthetase required for dimycocerosyl phthiocerol production, a major cell wall lipid that has been implicated in innate resistance to macrolides in *M. avium* (Philalay et al., 2004) and described in other *M. tuberculosis* drug-resistant strains (Farhat et al., 2013). This pattern of spatially clustered polymorphisms, previously observed in KZN-R506 (Ioerger et al., 2009), is highly unexpected, as TB has a low mutation rate. The longest open reading frame in *M. tuberculosis*, *pkS12* spans 12,456 nucleotides and is composed of two near identical sequences (Fig. S1). Eight of the SNVs were clustered at 5' Beta-ketoacyl synthase (bks) domain, after which the surrounding DNA sequence is identical to the corresponding sequence at the 3' bks domain. Taken together, these findings suggest a recombination event had occurred rather than multiple independent point mutations (Feil et al., 2000). *pkS12* has been identified by prior association studies in *M. tuberculosis* (Farhat et al., 2013); however, given the length of the gene, its association with amoxicillin/clavulanate susceptibility may well be spurious.

3.9. Amoxicillin/Clavulanate Susceptibility Within the LAM4 Phylogeny

In order to track the co-evolution of amoxicillin/clavulanate hyper-susceptibility and first and second-line drug-resistance within LAM4, we investigated the significant SNVs in relationship to the LAM4

phylogeny (Fig. 3). A key observation was that 21/38 (55%) of the variants identified in our analyses were grouped into only four aggregates (indicated as A to D in Fig. 3), and each associated with a distinct division in the LAM4 sub-clade (Table 3). Division B coincided with *rpoB* L452, which confers rifampicin resistance and emergence of MDR level drug-resistance. This analysis suggests that within the LAM4 subclade, MDR level-resistance and amoxicillin/clavulanate susceptibility appear to have emerged in tandem.

All the SNVs associated with divisions A–D occurred solely within the LAM4 clade, thus further analysis in other populations will be required to determine whether these SNVs represent markers of amoxicillin/clavulanate susceptibility among the broader *M. tuberculosis* population.

4. Discussion

The global increase in MDR and XDR TB has prompted investigators to search for alternative treatment options, including repurposing of existing antibiotic therapies (Wong et al., 2013). While *M. tuberculosis* has traditionally been considered resistant to the β-lactams, there is emerging evidence that meropenem/clavulanate can have anti-tubercular activity relevant to the treatment of XDR-TB (Hugonnet et al., 2009). However, the extent to which meropenem/clavulanate or other β-lactam/β-lactamase inhibitor combinations are effective against the wider *M. tuberculosis* population is unclear.

We performed a phenotypic screen of 91 *M. tuberculosis* strains (Cohen et al., 2015) in order to determine the range of susceptibility to amoxicillin, amoxicillin/clavulanate, meropenem and meropenem/clavulanate. As expected, nearly all tested strains (94%) were susceptible to meropenem/clavulanate. Surprisingly, 45% of strains were also susceptible to amoxicillin/clavulanate, including a large proportion of MDR and XDR strains (58% each). As meropenem/clavulanate is intravenous, costly, and has multiple potential side effects (Linden, 2007), we chose to focus our investigation and discussion on amoxicillin/clavulanate, which is an inexpensive, oral, and globally accessible drug combination with an excellent safety profile (Salvo et al., 2009).




Fig. 3. Tracing the emergence of amoxicillin/clavulanate susceptibility within the LAM4 clade. A. Bayesian phylogeny of 91 *M. tuberculosis* isolates as represented in Fig. 2. The LAM4 clade is marked by the blue box and is magnified in B. Nodes with bootstrap support values >80% are marked by an asterisk. Nodes A–D define subclade divisions for which the corresponding pattern of genomic variants listed in Table 3 is conserved among all members of the subclade. Amoxicillin/clavulanate MICs (amoxicillin $\mu\text{g}/\text{mL}$, clavulanate concentration fixed at 2.5 $\mu\text{g}/\text{mL}$) are represented in a horizontal bar graph to the right of the tree. The bar graph is color-coded according to first and second-line drug susceptibility patterns as in Fig. 2. Historic LAM4 strains are identified by name: KZN605 (XDR), KZN1435 (MDR) and KZN4207 (first/second-line drug susceptible).

We sought to further investigate the phenomenon of amoxicillin/clavulanate susceptibility using comparative genomics. A phylogenetic analysis indicated that a large proportion of MDR and XDR isolates in our dataset were part of a LAM4 clade, which was responsible for the famed Tugela Ferry XDR outbreak in KwaZulu-Natal in 2005 (Gandhi et al., 2006), and still accounts for a considerable burden of XDR (Chihota et al., 2012; Müller et al., 2013; Gandhi et al., 2014). Additionally, a large proportion of amoxicillin/clavulanate susceptible isolates were also members of this clade, raising the possibility that this drug combination may be of benefit for individuals harboring these strains.

The pharmacodynamics of co-amoxiclav in the treatment of *M. tuberculosis* have not been formally studied. However for most bacteria the time above MIC ($T > \text{MIC}$) is considered the principal determinant of efficacy (Turnidge, 1998). The slow growth of *M. tuberculosis* means an extended $T > \text{MIC}$ is likely to be critical for this organism. Despite this multiple and high dosing of co-amoxiclav could achieve drug levels expected to be active against *M. tuberculosis* strains with an MIC of $\leq 4 \mu\text{g}/\text{mL}$ /2.5 $\mu\text{g}/\text{mL}$ amoxicillin/clavulanic acid (Chierakul et al., 2006).

Next we identified putative genomic markers of amoxicillin/clavulanate susceptibility through application of a phylogenetically-aware linear mixed model (LMM), which is suitable for samples where there is a large phenotypic variability within a group of closely related isolates (Supplementary material). The LMM identified 12 candidate variant patterns, comprising 38 unique variants (Table 3, Table S5). It should be remembered that despite the use of a phylogenetically-aware LMM, association analyses cannot separate the effects of genomic variants that show linkage disequilibrium (*i.e.* those that represent the same pattern), a factor which must be considered when interpreting our results. Consequently, we do not infer causality, but rather suggest that the variants identified here represent genomic markers of amoxicillin/clavulanate susceptibility, which warrant further investigation.

Although our analyses did identify a number of interesting variants, we did not identify any associations between amoxicillin/clavulanate susceptibility and variation in genes previously implicated for this phenotype *e.g.* mycobacterial L,D-transpeptidases, carboxypeptidases, penicillin-binding proteins (Dubé et al., 2012; Datta et al., 2006; Kumar et

al., 2012; Flores et al., 2005; Bhakta and Basu, 2002; Danilchanka et al., 2008; Dinesh et al., 2013; Fukuda et al., 2013; McDonough et al., 2005). Furthermore, we found no evidence that altered β -lactamase genetics or activity accounts for observed differences in amoxicillin/clavulanate susceptibility. All 91 strains had a wild type *blaC*, the gene that encodes for the primary β -lactamase of *M. tuberculosis*. All strains in which β -lactamase activity was assessed—including strains with low MICs to amoxicillin/clavulanate—demonstrated the ability to hydrolyze nitrocefin, a β -lactam. Despite these findings, it is still conceivable that differences in *blaC* expression may account for the observed range of β -lactam susceptibility, a hypothesis that will need to be tested in future experiments.

For *M. tuberculosis*, first and second-line drug susceptibility conforms to a classic model of drug resistance: wild type *M. tuberculosis* is susceptible to first and second-line antitubercular drugs (e.g. isoniazid, rifampin, ofloxacin, kanamycin etc.), and exposure to these same agents selects for resistant organisms. In contrast, our documentation of *M. tuberculosis* susceptibility to amoxicillin/clavulanate does not fit this classical model. Drug susceptible reference strains of *M. tuberculosis* and clinical isolates in basal phylogenetic groups (Figs. 2 and 3) had innate resistance to amoxicillin/clavulanate, yet clinical isolates were observed to be susceptible, suggesting that they had acquired susceptibility to these agents. To distinguish this phenomenon from the classic model of drug resistance, we have named this concept “paradoxical hypersusceptibility,” which we define as phenotypic drug susceptibility observed in an organism in which its wild type state has innate resistance to that respective drug.

Further study will be necessary to fully elucidate the epidemiology of *in vitro* and *in vivo* susceptibility to β -lactam/ β -lactamase inhibitor combinations globally and in other lineages of *M. tuberculosis*. The association between MDR and XDR clinical isolates and *in vitro* susceptibility to amoxicillin/clavulanate may provide effective treatment options for patients with XDR-TB, at least in regions of high LAM4 prevalence such as South Africa. However a recent study from Japan (Horita et al., 2014) suggests that drug-resistant strains with other genetic backgrounds also exhibit a similar phenotype. While the South African National TB program includes amoxicillin/clavulanate as part of a suggested drug regimen for XDR (*Management of Drug-resistant Tuberculosis Policy Guidelines*, 2012), only 61% of patients in a recently published long-term cohort of XDR in South Africa were prescribed this drug combination for at least some part of their treatment course (Pietersen et al., 2014). Given the poor treatment outcomes for XDR that have been reported, the fact that β -lactam drug susceptibility testing is not routinely performed, and relative safety of the drug, empiric addition of amoxicillin/clavulanate to patients with XDR-TB in South Africa may be advisable, although the optimal dosing regimen still needs to be established.

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.ebiom.2016.05.041>.

Author Contributions

KAC conceived of the project, designed the research, conducted experiments, analyzed data, and wrote the paper.

TEH contributed analytic tools, designed research, conducted experiments, analyzed data, and wrote the paper.

KLW designed research, conducted experiments, analyzed data, and wrote the paper.

OW contributed analytic tools, designed research, conducted experiments, analyzed data, and wrote the paper.

VM conducted experiments.

CY designed research, conducted experiments, analyzed data, and wrote the paper.

OS designed research, conducted experiments, and analyzed data.

RA designed research, conducted experiments, and analyzed data.

TC designed research, conducted experiments, and analyzed data.

YG designed research.

WRB designed the research.

ASP designed the research and wrote the paper.

All authors reviewed the manuscript.

Funding Information

KAC was supported by T32HL007633 of the National Heart, Lung and Blood Institute. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Conflicts of Interest

None declared.

Acknowledgements

We thank Eyal Privman for helpful discussions. We thank Anna Trigos for assistance with the gene-content analysis. We would like to thank Nonkqubela Bantubani of the Medical Research Council (MRC) in Durban, in addition to Drs. Max O'Donnell and Nesri Padayatchi for contributing clinical isolates of *M. tuberculosis*, which were used in this study. Lastly, we would like to thank Prof. Koleka P. Mlisana and Dr. Nomonde R. Mvelase of the KwaZulu-Natal National Health Laboratory Service and Dr. Gyanu Lamichhane for providing nitrocefin.

References

- Bantubani, N., Kabera, G., Connolly, C., et al., 2014. High rates of potentially infectious tuberculosis and multidrug-resistant tuberculosis (MDR-TB) among hospital inpatients in KwaZulu Natal, South Africa indicate risk of nosocomial transmission. *PLoS One* 9, e90868.
- Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing on JSTOR. *J. R. Stat. Soc.* 57, 289–300.
- Bhakta, S., Basu, J., 2002. Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from *Mycobacterium tuberculosis*. *Biochem. J.* 361, 635–639.
- Brennan, M.J., Delogu, G., 2002. The PE multigene family: a ‘molecular mantra’ for mycobacteria. *Trends Microbiol.* 10, 246–249.
- Casali, N., Nikolayevskyy, V., Balabanova, Y., et al., 2012. Microevolution of extensively drug-resistant tuberculosis in Russia. *Genome Res.* 22, 735–745.
- Chen, P.E., Shapiro, B.J., 2015. The advent of genome-wide association studies for bacteria. *Curr. Opin. Microbiol.* 25, 17–24.
- Chierakul, W., Wangboonskul, J., Singtoroj, T., et al., 2006. Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis. *J. Antimicrob. Chemother.* 58, 1215–1220.
- Chihota, V.N., Müller, B., Mlambo, C.K., et al., 2012. Population structure of multi- and extensively drug-resistant *Mycobacterium tuberculosis* strains in South Africa. *J. Clin. Microbiol.* 50, 995–1002.
- Cohen, K.A., Abeel, T., Manson McGuire, A., et al., 2015. Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of *Mycobacterium tuberculosis* isolates from KwaZulu-Natal. *PLoS Med.* 12, e1001880.
- Collins, L., Franzblau, S.G., 1997. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against *Mycobacterium tuberculosis* and *Mycobacterium avium*. *Antimicrob. Agents Chemother.* 41, 1004–1009.
- Danilchanka, O., Mailaender, C., Niederweis, M., 2008. Identification of a novel multidrug efflux pump of *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* 52, 2503–2511.
- Datta, P., Dasgupta, A., Singh, A.K., Mukherjee, P., Kundu, M., Basu, J., 2006. Interaction between FtsW and penicillin-binding protein 3 (PBP3) directs PBP3 to mid-cell, controls cell septation and mediates the formation of a trimeric complex involving FtsZ, FtsW and PBP3 in mycobacteria. *Mol. Microbiol.* 62, 1655–1673.
- Demay, C., Liens, B., Burguière, T., et al., 2012. SITVITWEB—a publicly available international multimarker database for studying *Mycobacterium tuberculosis* genetic diversity and molecular epidemiology. *Infect. Genet. Evol.* 12, 755–766.
- Dinesh, N., Sharma, S., Balganes, M., 2013. Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* <http://dx.doi.org/10.1128/AAC.01957-12>.
- Dubée, V., Triboulet, S., Mainardi, J.-L., et al., 2012. Inactivation of *Mycobacterium tuberculosis* L,D-transpeptidase LdtMt, by carbapenems and cephalosporins. *Antimicrob. Agents Chemother.* 56, 4189–4195.
- Farhat, M.R., Shapiro, B.J., Kieser, K.J., et al., 2013. Genomic analysis identifies targets of convergent positive selection in drug-resistant *Mycobacterium tuberculosis*. *Nat. Genet.* 45, 1183–1189.
- Feil, E.J., Smith, J.M., Enright, M.C., Spratt, B.G., 2000. Estimating recombinational parameters in *Streptococcus pneumoniae* from multilocus sequence typing data. *Genetics* 154, 1439–1450.

- Flores, A.R., Parsons, L.M., Pavelka, M.S., 2005. Characterization of novel *Mycobacterium tuberculosis* and *Mycobacterium smegmatis* mutants hypersusceptible to beta-lactam antibiotics. *J. Bacteriol.* 187, 1892–1900.
- Fukuda, T., Matsumura, T., Ato, M., et al., 2013. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. *MBio* 4 (e00472–12).
- Gagneux, S., Small, P.M., 2007. Global phylogeography of *Mycobacterium tuberculosis* and implications for tuberculosis product development. *Lancet Infect. Dis.* 7, 328–337.
- Gandhi, N.R., Moll, A., Sturm, A.W., et al., 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 368, 1575–1580.
- Gandhi, N.R., Brust, J.C.M., Moodley, P., et al., 2014. Minimal diversity of drug-resistant *Mycobacterium tuberculosis* strains, South Africa. *Emerg. Infect. Dis.* 20, 394–401.
- Gonzalo, X., Drobniewski, F., 2013. Is there a place for β -lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. *J. Antimicrob. Chemother.* 68, 366–369.
- Gupta, R., Lavollay, M., Mainardi, J.-L., Arthur, M., Bishai, W.R., Lamichhane, G., 2010. The *Mycobacterium tuberculosis* protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. *Nat. Med.* 16, 466–469.
- Hershberg, R., Lipatov, M., Small, P.M., et al., 2008. High functional diversity in *Mycobacterium tuberculosis* driven by genetic drift and human demography. *PLoS Biol.* 6, e311.
- Horita, Y., Maeda, S., Kazumi, Y., Doi, N., 2014. In vitro susceptibility of *Mycobacterium tuberculosis* isolates to an oral carbapenem alone or in combination with lactamase inhibitors. *Antimicrob. Agents Chemother.* 58, 7010–7014.
- Hugonnet, J.-E., Blanchard, J.S., 2007. Irreversible inhibition of the *Mycobacterium tuberculosis* beta-lactamase by clavulanate. *Biochemistry* 46, 11998–12004.
- Hugonnet, J., Tremblay, L.W., Boshoff, H.I., Barry, C.E., Blanchard, J.S., 2009. Meropenem-clavulanate is effective against extensively drug-resistant *Mycobacterium tuberculosis*. *Science* 323, 1215–1218 (80-).
- Ioerger, T.R., Koo, S., No, E.-G., et al., 2009. Genome analysis of multi- and extensively drug-resistant tuberculosis from KwaZulu-Natal, South Africa. *PLoS One* 4, e7778.
- Kamerbeek, J., Schouls, L., Kolk, A., et al., 1997. Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. *J. Clin. Microbiol.* 35, 907–914.
- Kang, H.M., Zaitlen, N.A., Wade, C.M., et al., 2008. Efficient control of population structure in model organism association mapping. *Genetics* 178, 1709–1723.
- Keener, A.B., 2014. Oldie but goodie: repurposing penicillin for tuberculosis. *Nat. Med.* 20, 976–978.
- Koenig, R., 2007. Tuberculosis. Few mutations divide some drug-resistant TB strains. *Science* 318, 901–902.
- Kumar, P., Arora, K., Lloyd, J.R., et al., 2012. Meropenem inhibits D,D-carboxypeptidase activity in *Mycobacterium tuberculosis*. *Mol. Microbiol.* 1–15.
- Larsen, M.H., Biermann, K., Tandberg, S., Hsu, T., Jacobs, W.R., 2007. Genetic manipulation of *Mycobacterium tuberculosis*. *Curr. Protoc. Microbiol.* (Chapter 10: Unit 10A.2).
- Lew, J.M., Kapopoulou, A., Jones, L.M., Cole, S.T., 2011. TubercuList—10 years after. *Tuberculosis (Edinb.)* 91, 1–7.
- Li, H., Durbin, R., 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754–1760.
- Li, H., Handsaker, B., Wysoker, A., et al., 2009. The sequence alignment/map format and SAMtools. *Bioinformatics* 25, 2078–2079.
- Linden, P., 2007. Safety profile of meropenem: an updated review of over 6000 patients treated with meropenem. *Drug Saf.* 30, 657–668.
- Liu, X., Gutacker, M.M., Musser, J.M., Fu, Y.-X., 2006. Evidence for recombination in *Mycobacterium tuberculosis*. *J. Bacteriol.* 188, 8169–8177.
- Lun, S., Guo, H., Onajole, O.K., et al., 2013. Indoleamides are active against drug-resistant *Mycobacterium tuberculosis*. *Nat. Commun.* 4, 2907.
- Lun, S., Miranda, D., Kubler, A., et al., 2014. Synthetic lethality reveals mechanisms of *Mycobacterium tuberculosis* resistance to β -lactams. *MBio* 5 (e01767–14).
- Department of Health Republic of South Africa. Management of Drug-resistant Tuberculosis Policy Guidelines.
- Matsunaga, I., Sugita, M., 2012. MycoKetide: a CD1c-presented antigen with important implications in mycobacterial infection. *Clin. Dev. Immunol.* 2012. <http://dx.doi.org/10.1155/2012/981821>.
- McDonough, J.A., Hacker, K.E., Flores, A.R., Pavelka, M.S., Braunstein, M., 2005. The twin-arginine translocation pathway of *Mycobacterium smegmatis* is functional and required for the export of mycobacterial β -lactamases. *J. Bacteriol.* 187, 7667–7679.
- Müller, B., Chihota, V.N., Pillay, M., et al., 2013. Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa. *PLoS One* 8, e70919.
- O'Donnell, M.R., Wolf, A., Werner, L., Horsburgh, C.R., Padayatchi, N., 2014. Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study. *J. Acquir. Immune Defic. Syndr.* 67, 22–29.
- Pang, X., Samten, B., Cao, G., et al., 2013. MprAB regulates the espA operon in *Mycobacterium tuberculosis* and modulates ESX-1 function and host cytokine response. *J. Bacteriol.* 195, 66–75.
- Payen, M.C., De Wit, S., Martin, C., et al., 2012. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. *Int. J. Tuberc. Lung Dis.* 16, 558–560.
- Philalay, J.S., Palermo, C.O., Hauge, K.A., Rustad, T.R., Cangelosi, G.A., 2004. Genes required for intrinsic multidrug resistance in *Mycobacterium avium*. *Society* 48, 3412–3418.
- Pietersen, E., Ignatius, E., Streicher, E.M., et al., 2014. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. *Lancet* 383, 1230–1239.
- Ronquist, F., Teslenko, M., Van Der Mark, P., et al., 2012. MrBayes 3.2: efficient Bayesian phylogenetic inference and model choice across a large model space. *Syst. Biol.* 61, 539–542.
- Safi, H., Lingaraju, S., Amin, A., et al., 2013. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl- β -D-arabinose biosynthetic and utilization pathway genes. *Nat. Genet.* 45, 1190–1197.
- Salvo, F., De Sarro, A., Caputi, A.P., Polimeni, G., 2009. Amoxicillin and amoxicillin plus clavulanate: a safety review. *Expert Opin. Drug Saf.* 8, 111–118.
- Seemann, T., 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068–2069.
- Shabbeer, A., Cowan, L.S., Ozcaglar, C., et al., 2012. TB-lineage: an online tool for classification and analysis of strains of *Mycobacterium tuberculosis* complex. *Infect. Genet. Evol.* 12, 789–797.
- Turnidge, J.D., 1998. The pharmacodynamics of beta-lactams. *Clin. Infect. Dis.* 27, 10–22.
- Walker, B.J., Abeel, T., Shea, T., et al., 2014. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLoS One* 9, e112963.
- Wang, F., Cassidy, C., Sacchettini, J.C., 2006. Crystal structure and activity studies of the *Mycobacterium tuberculosis* beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. *Antimicrob. Agents Chemother.* 50, 2762–2771.
- Wei, Z., Wang, W., Hu, P., Lyon, G.J., Hakonarson, H., 2011. SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data. *Nucleic Acids Res.* 39, e132.
- White, A.R., Kaye, C., Poupard, J., Pypstra, R., Woodnutt, G., Wynne, B., 2004. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. *J. Antimicrob. Chemother.* 53 (Suppl. 1), i3–20.
- WHO, 2014. Global Tuberculosis Report.
- Wong, E.B., Cohen, K.A., Bishai, W.R., 2013. Rising to the challenge: new therapies for tuberculosis. *Trends Microbiol.* 21, 493–501.